Publications 2019

Madssen TS, Cao MD, Pladsen AV, Ottestad L, Sahlberg KK, Bathen TF, Giskeødegård GF (2019)
Historical Biobanks in Breast Cancer Metabolomics- Challenges and Opportunities
Metabolites, 9 (11)
DOI 10.3390/metabo9110278, PubMed 31766128

Ottestad L, Fronth L, Rajendiran S, Hege Aksnes L, Eikesdal HP, Støre Blix E, Ewertz M (2019)
Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer
Acta Oncol, 58 (3), 385-387
DOI 10.1080/0284186X.2019.1566771, PubMed 30798641

Publications 2017

Fleischer T, Klajic J, Aure MR, Louhimo R, Pladsen AV, Ottestad L, Touleimat N, Laakso M, Halvorsen AR, Grenaker Alnæs GI, Riis ML, Helland Å, Hautaniemi S, Lønning PE, Naume B, Børresen-Dale AL, Tost J, Kristensen VN (2017)
DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival
Oncotarget, 8 (1), 1074-1082
DOI 10.18632/oncotarget.13718, PubMed 27911866

Publications 2013

Margolin AA, Bilal E, Huang E, Norman TC, Ottestad L, Mecham BH, Sauerwine B, Kellen MR, Mangravite LM, Furia MD, Vollan HK, Rueda OM, Guinney J, Deflaux NA, Hoff B, Schildwachter X, Russnes HG, Park D, Vang VO, Pirtle T, Youseff L, Citro C, Curtis C, Kristensen VN, Hellerstein J et al. (2013)
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer
Sci Transl Med, 5 (181), 181re1
DOI 10.1126/scitranslmed.3006112, PubMed 23596205

Publications 2012

Engebraaten O, Edvardsen H, Løkkevik E, Naume B, Kristensen V, Ottestad L, Natarajan V (2012)
Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial
ISRN Oncol, 2012, 176789
DOI 10.5402/2012/176789, PubMed 22666610

Publications 2006

Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J (2006)
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
Breast Cancer Res, 8 (2), R13
DOI 10.1186/bcr1384, PubMed 16542503

Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, Ashley S, Smith I, Ottestad L, Kanis J (2006)
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] (vol 8, pg R13, 2006)
Breast Cancer Res., 8 (3), 406
DOI 10.1186/bcr1413

Publications 2005

Helle SI, Mietlowski W, Guastalla JP, Szakolczai I, Bajetta E, Sommer H, Baltali E, Pinter T, Csepreghy M, Ottestad L, Boni C, Bryce C, Klijn JG, Lønning PE (2005)
Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy
Eur J Cancer, 41 (5), 694-701
DOI 10.1016/j.ejca.2004.12.015, PubMed 15763644

Publications 2003

Brustugun OT, Nome O, Bruland S ØS, Ottestad L, Lilleby W (2003)
[Breast cancer patients' assessment of waiting time before radiotherapy]
Tidsskr Nor Laegeforen, 123 (12), 1685-6
PubMed 12821991

Publications 2002

Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L (2002)
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer
J Clin Oncol, 20 (15), 3219-24
DOI 10.1200/JCO.2002.11.080, PubMed 12149294

Publications 2001

Geisler J, Detre S, Berntsen H, Ottestad L, Lindtjørn B, Dowsett M, Einstein Lønning P (2001)
Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer
Clin Cancer Res, 7 (5), 1230-6
PubMed 11350888

Suo Z, Bjaamer A, Ottestad L, Nesland JM (2001)
Expression of EGFR family and steroid hormone receptors in ductal carcinoma in situ of the breast
Ultrastruct Pathol, 25 (5), 349-56
DOI 10.1080/019131201317101216, PubMed 11758715

Publications 1999

Ottestad L, Wang H (1999)
Prøveprosjekt med masseundersøkelse for brystkreft ved mammografi: evaluering av 1. screeningrunde
In Forskningsrapport, Kreftregisteret, Oslo, nr 2, 1999, III, 23 s.
BIBSYS 991456068, ISBN 82-90343-45-0

Publications 1997

Laake K, Odegård A, Andersen TI, Bukholm IK, Kåresen R, Nesland JM, Ottestad L, Shiloh Y, Børresen-Dale AL (1997)
Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM
Genes Chromosomes Cancer, 18 (3), 175-80
DOI 10.1002/(SICI)1098-2264(199703)18:3<175::AID-GCC4>3.3.CO;2-R, PubMed 9071570

Publications 1996

Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lønning PE (1996)
Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer
Br J Cancer, 74 (8), 1286-91
DOI 10.1038/bjc.1996.531, PubMed 8883419

Publications 1995

Schjølseth SA, Hagen T, Ottestad L, Jakobsen E (1995)
[Chemotherapy-induced hemolytic uremic syndrome. A complication to mitomycin treatment of breast carcinoma]
Tidsskr Nor Laegeforen, 115 (27), 3371-3
PubMed 7491579

Publications 1993

Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen AL (1993)
Prognostic significance of TP53 alterations in breast carcinoma
Br J Cancer, 68 (3), 540-8
DOI 10.1038/bjc.1993.383, PubMed 8102535

Ottestad L (1993)
Human breast carcinoma: clinical relevance of cellular proliferation, DNA ploidy and proto-oncogene activation
The Norwegian Radium Hospital, Oslo, 1 b. (flere pag.)
BIBSYS 93064784x, ISBN 82-7633-026-6

Ottestad L, Andersen TI, Nesland JM, Skrede M, Tveit KM, Nustad K, Børresen AL (1993)
Amplification of c-erbB-2, int-2 and c-myc genes in node-negative breast carcinomas. Relationship to prognosis
Acta Oncol, 32 (3), 289-94
DOI 10.3109/02841869309093597, PubMed 8100712

Ottestad L, Pettersen EO, Nesland JM, Hannisdal E, Fosså SD, Tveit KM (1993)
Flow cytometric DNA analysis as prognostic factor in human breast carcinoma
Pathol Res Pract, 189 (4), 405-10
DOI 10.1016/S0344-0338(11)80327-4, PubMed 8351241

Publications 1992

Andersen TI, Gaustad A, Ottestad L, Farrants GW, Nesland JM, Tveit KM, Børresen AL (1992)
Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas
Genes Chromosomes Cancer, 4 (2), 113-21
DOI 10.1002/gcc.2870040203, PubMed 1373310

Børresen AL, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, Ottestad L, Smith-Sørensen B, Hovig E, Malkin D (1992)
Screening for germ line TP53 mutations in breast cancer patients
Cancer Res, 52 (11), 3234-6
PubMed 1591732

Nesland JM, Grude TH, Ottestad L, Johannessen JV (1992)
Invasive lobular carcinoma of the breast. The importance of an alveolar growth pattern
Pathol Annu, 27 Pt 1, 233-47
PubMed 1736244

Publications 1991

Nesland JM, Ottestad L, Børresen AL, Tvedt KE, Holm R, Heikkilä R, Tveit K (1991)
The c-erbB-2 protein in primary and metastatic breast carcinomas
Ultrastruct Pathol, 15 (3), 281-9
DOI 10.3109/01913129109021890, PubMed 1678562

Nesland JM, Ottestad L, Heikilla R, Holm R, Tveit K, Børresen AL (1991)
C-erbB-2 protein and neuroendocrine expression in breast carcinomas
Anticancer Res, 11 (1), 161-7
PubMed 1673329

Publications 1990

Børresen AL, Ottestad L, Gaustad A, Andersen TI, Heikkilä R, Jahnsen T, Tveit KM, Nesland JM (1990)
Amplification and protein over-expression of the neu/HER-2/c-erbB-2 protooncogene in human breast carcinomas: relationship to loss of gene sequences on chromosome 17, family history and prognosis
Br J Cancer, 62 (4), 585-90
DOI 10.1038/bjc.1990.334, PubMed 1977466

Tretli S, Haldorsen T, Ottestad L (1990)
The effect of pre-morbid height and weight on the survival of breast cancer patients
Br J Cancer, 62 (2), 299-303
DOI 10.1038/bjc.1990.282, PubMed 2386747

Tveit KM, Ottestad L (1990)
Drug sensitivity testing of human breast cancer
Acta Oncol, 29 (3), 335-8
DOI 10.3109/02841869009090010, PubMed 2194534

Publications 1989

Kotańska KM, Holm R, Ottestad L, Nesland JM (1989)
An ultrastructural study of benign and malignant breast epithelial cells. A search for tonofilaments
J Submicrosc Cytol Pathol, 21 (3), 469-74
PubMed 2551480

KOTANSKA KM, HOLM R, OTTESTAD L, NESLAND JM (1989)
AN ULTRASTRUCTURAL-STUDY OF BENIGN AND MALIGNANT BREAST EPITHELIAL-CELLS - A SEARCH FOR TONOFILAMENTS
J. Submicrosc. Cytol. Pathol., 21 (3), 469-474

Lilleng R, Hagmar B, Myrtvedt M, Ottestad L (1989)
[Determination of estrogen receptors in fine-needle aspirates from breast carcinoma. A description of a method]
Tidsskr Nor Laegeforen, 109 (15), 1630-2
PubMed 2741142

Ottestad L, Tveit KM, Hannisdal E, Skrede M, Nesland JM, Gundersen S, Pihl A (1989)
Colony forming ability of human breast carcinomas: lack of prognostic significance
Br J Cancer, 60 (2), 216-9
DOI 10.1038/bjc.1989.254, PubMed 2765368

Publications 1988

Erikstein B, Nesland JM, Ottestad L, Lund E, Johannessen JV (1988)
Neuron specific enolase-positive breast carcinomas
Histol Histopathol, 3 (1), 97-102
PubMed 2980214

Nesland JM, Holm R, Ottestad L, Karlsen KO, Johannessen JV (1988)
Neuroendocrine activity in metastatic breast carcinomas
APMIS Suppl, 2, 204-14
PubMed 2846016

NESLAND JM, HOLM R, OTTESTAD L, KARLSEN KO, JOHANNESSEN JV (1988)
NEURO-ENDOCRINE ACTIVITY IN METASTATIC BREAST CARCINOMAS
APMIS, 96 2, 204-214

Ottestad L, Tveit KM, Høifødt HK, Nesland JM, Vaage S, Høie J, Lund E, Pihl A (1988)
Cultivation of human breast carcinoma in soft agar. Experience with 237 fresh tumour specimens
Br J Cancer, 58 (1), 8-12
DOI 10.1038/bjc.1988.151, PubMed 3048354

Publications 1986

Saeter G, Ottestad L, Karlsen KO (1986)
[Implanted subcutaneous injection port. When is continuous venous access needed]
Tidsskr Nor Laegeforen, 106 (7), 577-9
PubMed 3961785